SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Pulse Biosciences, Inc. (PLSE)

NEW YORK, Sept. 11, 2017

The investigation concerns whether Pulse and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On September 11, 2017, Pulse disclosed in a regulatory filing "that it has withdrawn its initial application to the United States Food and Drug Administration (FDA) for 510(k) clearance of its PulseTxTM System." Pulse further disclosed that the "voluntary withdrawal on September 8, 2017, was the result of the FDA's appropriate request for additional data that could not be provided within the Agency's 90-day review period that would have otherwise ended on September 10, 2017." On this news, shares of Pulse fell sharply during intraday trading on September 11, 2017.

If you are aware of any facts relating to this investigation, or purchased Pulse shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/plse. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact: